Objective: To explore the effects of different antihypertensive strategies on blood pressure and urinary albumin excretion in patients with hypertension and microalbuminuria.
Methods: For this multi-center, randomized, positively controlled clinical trial, a total of 531 patients with mild-to-moderate essential hypertension and microalbuminuria were enrolled. They were divided randomly into calcium channel blocker (CCB), angiotensin II receptor antagonist (ARB) and CCB+ARB groups. The whole treatment period was 6 months.
Results: According to ANOVA analysis, the post-therapeutic urinary albumin level decreased 20.6, 27.6 and 30.9 mg/L in CCB, ARB and CCB+ARB groups respectively (P = 0.067). And the extents of urinary albumin reduction were 31.1 and 6.6 mg/L in patients with controlled and uncontrolled blood pressure respectively (P < 0.001).
Conclusion: Effective antihypertensive therapy is a key for decreasing urinary albumin excretion in hypertensive patients. As compared with calcium antagonists, ARB-containing regimens appear to be better in reducing urinary albumin.